AML with RUNX1 mutation was considered as adverse-risk AML by the ELN and new provisional entity in the 2016 WHO classification given its characteristic clinicopathologic features and inferior outcome in adult AML [13, 16–18, 20]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.